Nuvectis Pharma (NVCT)
NASDAQ:NVCT
Want to see NVCT full AI Analyst Report?
NVCT Stock Chart & Stats
$8.90
-$0.26(-4.17%)
At close: 4:00 PM EST
$8.90
-$0.26(-4.17%)
Day’s Range― - ―
52-Week Range$5.55 - $11.15
Previous CloseN/A
Volume31.37K
Average Volume (3M)89.48K
Market Cap
$235.51M
Enterprise Value$203.88M
Total Cash (Recent Filing)$31.63M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Aug 11, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding26,491,701
10 Day Avg. Volume112,705
30 Day Avg. Volume89,483
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)8.94
Price to Sales (P/S)0.00
P/FCF Ratio-10.29
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.39
Forecast
1Y Price Target
$13.50Price Target Upside51.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.27
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Design And EnrollmentA Phase 1b program that includes monotherapy and combination cohorts, including an arm with an EGFR inhibitor, and allows broader entry criteria may accelerate enrollment and generate multiple clinical readouts.
Mechanism And Preclinical DataPreclinical evidence indicates NXP900 can lower YES1/YAP1 activity and resensitize tumors to EGFR and ALK therapies, supporting a plausible mechanism for clinical benefit in resistant lung cancer.
Unmet Patient Need And Potential Market ImpactNXP900's ability to potentially restore sensitivity in patients who have exhausted EGFR and ALK options addresses a clear treatment gap and could meaningfully enhance the drug's clinical value if efficacy is confirmed.
Bears Say
Class Efficacy RiskPrior attempts to combine Src inhibitors with other cancer therapies failed, creating class-level skepticism that could weigh on confidence in NXP900's ability to deliver clinical benefit.
Financial Results And Capital RiskEarnings per share slightly below analyst and consensus estimates increases near-term financial concern and could pressure valuation and access to funding if revenue or growth assumptions are challenged.
Target Engagement RiskHistorical failures were linked to insufficient inhibition of the intended target, posing a specific risk that NXP900 may not achieve the necessary target engagement to drive tumor responses.
Nuvectis Pharma News
NVCT FAQ
What was Nuvectis Pharma’s price range in the past 12 months?
Nuvectis Pharma lowest stock price was $5.55 and its highest was $11.15 in the past 12 months.
What is Nuvectis Pharma’s market cap?
Nuvectis Pharma’s market cap is $235.51M.
When is Nuvectis Pharma’s upcoming earnings report date?
Nuvectis Pharma’s upcoming earnings report date is Aug 11, 2026 which is in 98 days.
How were Nuvectis Pharma’s earnings last quarter?
Nuvectis Pharma released its earnings results on May 05, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.314 by $0.054.
Is Nuvectis Pharma overvalued?
According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued.
Does Nuvectis Pharma pay dividends?
Nuvectis Pharma does not currently pay dividends.
What is Nuvectis Pharma’s EPS estimate?
Nuvectis Pharma’s EPS estimate is -0.32.
How many shares outstanding does Nuvectis Pharma have?
Nuvectis Pharma has 26,491,701 shares outstanding.
What happened to Nuvectis Pharma’s price movement after its last earnings report?
Nuvectis Pharma reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.314. Following the earnings report the stock price went up 0.458%.
Which hedge fund is a major shareholder of Nuvectis Pharma?
Currently, no hedge funds are holding shares in NVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvectis Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.50 (51.69% Upside)
$13.50 (51.69% Upside)
Blogger Sentiment
Bearish
NVCT Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Negative
20 days / 200 days
Momentum
82.74%
12-Months-Change
Fundamentals
Return on Equity
-131.80%
Trailing 12-Months
Asset Growth
70.41%
Trailing 12-Months
Company Description
Nuvectis Pharma
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
NVCT Stock 12 Month Forecast
Average Price Target
$13.50
▲(51.69% Upside)
Technical Analysis
Nkarta
―
Orchestra BioMed Holdings
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
42.07% Insiders
4.30% Mutual Funds
4.24% Other Institutional Investors
44.52% Public Companies and
Individual Investors